phage
display
select
techniqu
peptid
protein
fuse
bacteriophag
coat
protein
display
surfac
virion
technolog
first
describ
georg
p
smith
demonstr
display
peptid
filament
phage
fuse
peptid
interest
gene
iii
filament
phage
phagedisplay
random
peptid
librari
enabl
function
access
peptid
provid
physic
link
phenotyp
display
peptid
genotyp
encod
dna
librari
lend
screen
process
bind
clone
separ
nonbind
clone
affin
purif
peptid
bind
individu
target
identifi
affin
select
call
biopan
biopan
display
librari
incub
immobil
target
follow
extens
wash
remov
nonreact
phage
binder
usual
elut
use
acid
high
salt
enrich
amplif
appropri
host
cell
three
five
round
biopan
usual
perform
order
obtain
target
bind
high
affin
fig
primari
structur
peptid
determin
sequenc
dna
individu
clone
use
approach
easi
identifi
peptid
bind
specif
target
molecul
phagedisplay
peptid
librari
use
bcell
tcell
epitop
map
select
bioactiv
peptid
bound
receptor
protein
select
diseasespecif
antigen
mimic
select
peptid
bound
nonprotein
target
select
cellspecif
peptid
select
organspecif
peptid
develop
peptidemedi
drug
deliveri
system
applic
target
peptid
identifi
use
phagedisplay
peptid
librari
potenti
use
basic
research
translat
medicin
review
paper
discuss
detail
applic
phagedisplay
technolog
platform
biomed
scienc
upon
encount
antigen
host
humor
immun
activ
trigger
product
antibodi
direct
foreign
protein
epitop
knowledg
protein
epitop
pivot
understand
pathogenesi
pathogen
infect
develop
diagnost
reagent
therapeut
antibodi
effect
vaccin
epitop
known
antigen
determin
recogn
compon
immun
system
includ
antibodi
b
cell
cell
epitop
antigen
depend
structur
properti
either
linear
conform
linear
epitop
continu
amino
acid
sequenc
antigen
correspond
primari
structur
contrast
conform
epitop
contain
discontinu
amino
acid
sequenc
antigen
base
protein
tertiari
structur
sever
experiment
method
identifi
bcell
epitop
pepscan
cocrystal
nuclear
magnet
reson
nmr
comput
dock
sitedirect
mutagenesi
phage
display
method
provid
econom
rapid
approach
map
bcell
epitop
previou
studi
use
variou
phagedisplay
random
peptid
librari
identifi
bcell
epitop
neutral
epitop
monoclon
antibodi
mab
addit
mab
polyclon
antibodi
eg
special
sera
patient
immun
mice
also
captur
solid
disk
magnet
bead
react
comprehens
librari
random
peptid
peptid
select
biopan
antibodi
complex
sera
patient
variou
diseas
includ
sever
acut
respiratori
syndrom
sar
infect
human
papillomaviru
hpv
avian
influenza
virus
aiv
base
inform
bcell
epitop
polyclon
antibodi
certain
peptidebas
antigen
use
serolog
diagnosi
suitabl
develop
vaccin
select
diseasespecif
epitop
may
prove
invalu
identif
etiolog
agent
fig
consider
potenti
phage
display
peptid
librari
lie
capac
identifi
peptid
molecul
mimic
epitop
name
mimotop
mimotop
fewer
similar
primari
amino
acid
antigen
alway
show
discontinu
sequenc
elicit
ident
highli
similar
antibodi
respons
nativ
epitop
develop
diagnost
prevent
reagent
requir
screen
phagedisplay
peptid
librari
diseasespecif
epitopesmimotop
serum
cerebrospin
fluid
sampl
obtain
patient
viral
infect
rheumatoid
arthriti
multipl
sclerosi
autoimmun
thrombocytopen
purpura
neurocysticercosi
peptid
select
biopan
serum
sampl
patient
infect
hpv
sar
aiv
mimotopebas
detect
suitabl
broad
spectrum
antibodi
avian
influenza
viru
shown
improv
serolog
detect
sar
rheumatoid
arthriti
anoth
exampl
recent
identifi
cholera
toxinbind
peptid
cholera
toxin
secret
vibrio
cholera
enter
host
cell
bind
monosialogangliosid
would
result
acut
diarrhea
biopan
cholera
toxin
b
ctb
subunit
select
ctbbind
peptid
structur
mimic
could
serv
novel
agent
block
ctb
bind
epitheli
cell
prevent
ensu
physiolog
effect
cholera
toxin
mimotop
also
use
character
unknown
initi
event
provid
clue
toward
diseas
pathogenesi
biopan
antibodi
system
sclerosi
patient
use
screen
immunoposit
peptid
high
degre
similar
autoantigen
includ
heterogen
ribonucleoprotein
hnrnp
cytochrom
c
fibrillarin
late
protein
human
cytomegaloviru
cmv
immunoposit
peptidebas
affin
purifi
antibodi
sera
system
sclerosi
patient
react
surfac
compon
endotheli
cell
induc
apoptosi
dengu
antibodi
bcell
epitop
crossreact
astrocyt
elev
human
protein
human
endotheli
cell
may
caus
dengu
patient
suffer
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
recent
antigen
peptid
mimick
glycoprotein
also
known
fetuina
identifi
serum
antibodi
prostat
cancer
patient
use
antigen
mimic
peptid
author
demonstr
increas
serum
antibodi
reactiv
fetuina
diseas
progress
index
patient
strong
serum
reactiv
larg
cohort
metastat
prostat
cancer
patient
mention
studi
diseasespecif
antigen
mimic
phage
display
help
us
understand
etiolog
diseas
fig
membran
receptor
pivot
cellcel
biochem
electr
signal
essenti
physiolog
function
therefor
pharmaceut
industri
tend
focu
develop
drug
target
membran
receptor
novel
receptor
ligand
discov
use
phagedisplay
random
peptid
librari
may
either
agonist
antagonist
fig
two
typic
exampl
agonist
peptid
select
phage
display
peptid
target
erythropoietin
receptor
epor
thrombopoietin
receptor
tpor
treatment
epo
mimet
peptid
conform
chang
extracellular
domain
epor
trigger
intracellular
signal
transduct
discoveri
may
form
basi
design
small
molecul
mimet
epo
hand
select
small
peptid
target
tpor
compet
bind
natur
ligand
thrombopoietin
stimul
prolifer
tporespons
cell
line
antagonist
membran
receptor
phage
display
also
report
exampl
vascular
endotheli
growth
factor
vegf
play
import
role
angiogenesi
bind
kinas
domain
receptor
peptid
antagonist
block
vegfmedi
angiogenesi
obtain
phage
display
human
cxc
ligand
type
chemoattract
bind
involv
inflamm
inhibit
bind
antagonist
peptid
investig
use
develop
new
therapeut
treatment
inflammatori
diseas
phage
display
also
use
isol
receptorindepend
peptid
modul
g
proteincoupl
receptor
select
peptid
g
protein
interact
subunit
lead
elev
sensit
guanin
nucleotid
bind
adenosin
receptor
subunit
order
enhanc
dissoci
g
protein
heterotrim
vitro
activ
g
protein
signal
intact
cell
pathogenesi
diseas
occur
express
abnorm
enzym
serv
potenti
target
develop
inhibitor
new
drug
block
activ
enzym
phage
display
use
identifi
peptid
substrat
inhibitor
modul
enzym
activ
fig
filament
phage
resist
wide
rang
proteas
use
identifi
substrat
gener
proteas
inhibitor
bahudhanapati
et
al
identifi
select
inhibitor
metalloproteinas
screen
variant
tissu
inhibitor
use
phage
display
broad
rang
inhibitor
matrix
metalloproteinas
mmp
addit
proteas
inhibitor
peptidebas
inhibitor
variou
enzym
human
hmgcoa
reductas
ubiquitin
ligas
tyrosinas
identifi
phagedisplay
random
peptid
librari
cell
proteinprotein
interact
regul
mechan
sever
import
normal
physiolog
function
phage
display
potent
versatil
method
studi
proteinprotein
interact
appli
wide
rang
protein
interact
partner
use
number
applic
especi
map
intracellular
interact
distinct
protein
domain
good
exampl
protein
interact
partner
includ
src
homolog
sh
domain
highli
conserv
protein
interact
modul
compris
amino
acid
domain
also
found
varieti
function
unrel
protein
et
al
gener
librari
human
domain
express
surfac
bacteriophag
therebi
enabl
analysi
human
domain
bind
target
protein
interest
includ
human
immunodefici
nef
kinas
pak
voss
et
al
also
establish
similar
librari
defin
domain
react
intracellular
region
fa
ligand
addit
known
domain
author
also
identifi
number
addit
domain
may
also
associ
fasl
cellular
adapt
protein
contain
gyf
domain
ctermin
fragment
kofler
et
al
identifi
new
conserv
motif
ppg
wfyml
gyf
domain
use
phage
display
align
consensu
motif
protein
databas
combin
yeast
display
nmr
method
allow
scientist
rapidli
identifi
novel
interact
partner
gyf
domain
mani
differ
type
bacteria
trigger
protect
immun
respons
cell
surfac
nonprotein
antigen
polysaccharid
mani
tumor
antigen
carbohydr
epitop
mimick
low
immunogen
polysaccharid
carbohydr
antigen
screen
identifi
phagedisplay
random
peptid
librari
fig
isol
peptid
mimotop
coupl
carrier
protein
use
potenti
vaccin
candid
stimul
stronger
antibodi
respons
phage
display
techniqu
also
allow
us
identifi
novel
peptid
rna
interest
screen
random
peptid
librari
select
peptid
target
helix
bacteri
rna
use
inhibit
cellfre
translat
bose
et
al
use
phage
display
find
select
peptid
bind
block
dicer
process
decreas
express
studi
success
employ
peptid
phage
display
select
binder
small
molecul
fluorophor
microcystinlr
paclitaxel
taxol
recent
liu
et
al
perform
phage
display
screen
peptid
ligand
recogn
insecticid
imidacloprid
environment
monitor
water
soil
biopan
strategi
phage
display
use
select
specif
peptid
nanomateri
phagedisplay
nanomateri
bind
peptid
broadli
use
field
nanotechnolog
whaley
et
al
show
power
use
combinatori
phagedisplay
librari
select
highli
specif
peptid
bind
rang
crystallin
semiconductor
structur
gaa
depend
nanocryst
orient
applic
specif
peptid
extend
recogn
substrat
inorgan
nanocryst
includ
zn
cd
well
magnet
materi
peptid
deriv
phagedisplay
librari
specif
bound
conduct
polym
use
biomateri
function
surfac
conduct
polym
therebi
enabl
variou
electron
biomed
applic
moreov
au
ag
ti
pt
pdbind
peptid
acquir
use
combinatori
phage
display
peptid
librari
metal
semiconductortarget
peptid
genet
engin
use
nano
biotechnolog
particularli
molecular
biomimet
field
peptid
phage
display
wholecel
pan
offer
highthroughput
approach
identifi
peptid
bind
specif
singl
cell
type
johnston
cowork
first
describ
use
peptidedisplay
phage
identifi
peptid
bind
sever
differ
cell
type
common
screen
method
process
call
biopan
shown
fig
bind
affin
target
phage
clone
enrich
perform
vitro
variou
type
cell
includ
cultur
cell
line
primari
cell
isol
anim
model
human
patient
process
cell
fix
cell
activ
cell
etc
within
past
ten
year
sever
studi
focus
vitro
biopan
phage
display
peptid
librari
use
variou
cancer
cell
type
identifi
cellspecif
ligand
depend
applic
ligand
select
perform
adher
fix
cell
experiment
approach
modifi
isol
phage
bind
cell
surfac
peptid
therebi
trigger
cellular
uptak
peptid
peptidedisplay
phage
librari
incub
cell
defin
period
time
cell
subsequ
wash
remov
nonspecif
weakli
bound
phage
order
reduc
crossreact
peptid
phage
block
agent
bsa
occasion
use
remov
unbound
phage
requir
obtain
phage
clone
strong
bind
desir
target
remov
nonspecif
bind
background
gener
wash
process
rel
gentl
howev
stringent
wash
may
increas
affin
select
phage
clone
case
neg
select
perform
avoid
aforement
problem
gener
neg
select
essenti
phage
bound
target
recov
use
sever
elut
strategi
includ
use
acid
buffer
dithiothreitol
high
ionic
strength
tend
decreas
interact
peptid
target
commonli
acid
buffer
suffici
elut
target
bound
phage
howev
case
strong
peptidetarget
interact
elut
procedur
may
partial
break
peptidetarget
interact
therebi
result
loss
highaffin
phage
clone
circumv
problem
strukelj
cowork
use
modifi
method
ultrasound
appli
acid
buffer
elut
releas
targetbound
phage
enabl
select
highaffin
phage
clone
case
ligand
particular
target
known
avail
competit
elut
prefer
method
isol
target
molecul
method
specif
elut
desir
targetbound
phage
clone
avoid
elut
backgroundbound
phage
altern
phage
also
elut
competit
nonspecif
use
free
target
molecul
eluant
ad
bacteri
host
directli
targetbound
phage
use
whole
cell
instead
purifi
protein
target
vitro
biopan
sever
advantag
cellular
receptor
express
live
cell
retain
nativ
state
correct
protein
fold
quaternari
structur
express
level
associ
neighbor
protein
biolog
function
activ
biopan
modifi
protocol
use
isol
peptid
mediat
specif
cellular
function
exampl
select
aim
isol
surfacebound
intern
peptid
direct
elut
phage
enabl
isol
surfacebound
phage
surfacebound
phage
remov
lowph
wash
treatment
proteas
phage
intern
characterist
isol
addit
use
whole
cell
biopan
enabl
identif
cell
surfac
molecul
unknown
biolog
function
use
character
cell
surfac
profil
provid
inform
molecular
chang
express
level
protein
local
normal
diseas
cell
although
numer
cellbind
peptid
success
isol
use
vitro
pan
cultur
cell
sever
challeng
still
remain
particular
systemat
experiment
approach
target
identif
lack
key
problem
accur
identif
peptidetarget
molecul
import
basic
clinic
research
convent
receptor
identif
focus
membran
protein
extract
affin
purif
follow
mass
spectrometr
identif
purifi
protein
howev
problem
associ
approach
aris
difficulti
maintain
nativ
interact
target
peptid
isol
whole
membran
receptor
furthermor
bind
affin
target
peptid
gener
low
enabl
purif
affinitybas
method
wu
cowork
aim
overcom
problem
outlin
use
biotinyl
peptid
directli
bind
intact
cell
subsequ
fixat
ligandreceptor
complex
crosslink
sulfosuccinimidyl
propion
dtssp
affin
trap
lcmsm
analysi
unknown
target
protein
plasma
membran
cell
could
identifi
import
note
advanc
peptid
identif
subsequ
receptor
identif
lead
discoveri
import
cellular
target
previous
unknown
improv
understand
molecul
express
patholog
state
may
also
provid
use
inform
molecul
express
normal
physiolog
condit
organspecif
peptid
isol
phage
display
peptid
librari
perform
select
live
anim
vivo
phage
display
technolog
first
describ
ruoslahti
cowork
aim
discov
brain
vasculatur
target
peptid
use
phagedisplay
peptid
librari
typic
random
peptid
phage
librari
introduc
intraven
inject
circul
anim
brief
circul
time
anim
sacrif
unbound
phage
clone
wash
perfus
left
ventricl
salin
base
halflif
phage
previou
studi
circul
time
peptidedisplay
phage
gener
estim
min
time
rang
evid
display
exogen
peptid
protein
exhibit
circul
halfliv
short
min
long
h
molenaar
cowork
report
degrad
phage
occur
rapidli
min
inject
circul
time
min
may
caus
lysosom
degrad
phage
uptak
target
tissu
remov
unbound
phage
circul
desir
organ
collect
homogen
organassoci
phage
recov
homogen
tissu
fraction
organ
lysat
use
infect
bacteria
phage
amplif
subsequ
round
select
anoth
anim
anoth
fraction
use
phage
titer
measur
amount
recov
phage
round
vivo
biopan
phage
titer
recov
target
tissu
increas
sever
peptid
motif
typic
identifi
given
organ
fig
biopan
specif
isol
peptid
need
confirm
gener
wild
type
phage
without
insert
phage
scrambl
peptid
use
neg
control
abil
isol
peptid
home
target
organ
confirm
either
compar
analysi
use
scrambl
peptid
competit
studi
use
combin
synthet
peptid
select
phage
clone
ident
peptid
sequenc
approach
immunostain
home
phage
fluoresc
radioact
label
either
phage
synthet
peptid
use
directli
determin
organ
tissu
distribut
approach
appli
number
differ
organ
includ
brain
kidney
lung
liver
uteru
muscl
pancrea
thymu
mammari
gland
variou
type
tumor
malign
tissu
vasculatur
target
use
phagedisplay
random
peptid
librari
addit
tumor
blood
vessel
mani
tumor
induc
growth
new
lymphat
vessel
chang
characterist
tumor
develop
sever
research
use
vivo
phage
display
technolog
map
tumorspecif
differ
lymphat
vasculatur
identifi
peptid
specif
home
tumor
lymphat
use
vivo
phage
display
technolog
identifi
specif
home
peptid
without
pitfal
peptid
isol
anim
model
use
method
may
translat
human
differ
vasculatur
peptid
bind
speci
limit
overcom
perform
biopan
human
phage
librari
inject
termin
human
patient
retriev
human
tissu
identifi
organ
specif
peptid
anoth
studi
report
use
phagedisplay
librari
cancer
patient
identifi
tumortarget
ligand
vivo
phage
display
shown
effect
power
techniqu
isol
peptid
specif
bind
organ
high
affin
specif
howev
optim
peptid
need
enhanc
clinic
applic
vivo
phage
display
research
deliveri
anticanc
drug
solid
tumor
limit
physic
transport
barrier
within
tumor
restrict
directli
contribut
decreas
therapeut
index
emerg
drug
resist
drug
deliveri
system
design
precis
spatiotempor
control
demonstr
potenti
enhanc
drug
deliveri
anim
model
mani
nanoparticl
deliveri
system
anticanc
drug
enter
clinic
shown
exert
anticanc
effect
improv
pharmacokinet
pharmacodynam
properti
associ
drug
liposom
advanc
form
particul
drug
carrier
liposom
system
like
resavoid
longcircul
system
confer
stabl
formul
improv
pharmacokinet
passiv
target
tumor
tissu
newest
gener
drug
carrier
util
multicap
nanotechnologyori
strategi
aim
greater
specif
effici
featur
direct
molecular
target
cancer
cell
via
ligandmedi
interact
molecular
target
drug
deliveri
achiev
use
target
liposom
creat
link
liposom
drug
specif
ligand
develop
target
liposom
made
possibl
advanc
liposom
system
two
technolog
principl
fulli
integr
thu
combin
specif
ligand
drug
deliveri
capabl
liposom
fig
peptidemedi
liposom
includ
three
main
compon
anticanc
drug
liposom
carrier
target
ligand
fig
remot
load
method
ammonium
sulfat
method
ph
gradient
method
encapsul
weak
base
doxorubicin
vinorelbin
liposom
effici
scheduledepend
drug
vinca
alkaloid
topotecan
reason
candid
liposom
deliveri
effect
enhanc
exposur
time
cancer
cell
therapeut
drug
level
use
peptidemedi
liposom
also
avoid
expos
normal
tissu
cytotox
drug
prevent
advers
side
effect
high
tumor
interstiti
fluid
pressur
ifp
barrier
effici
drug
deliveri
increas
ifp
contribut
decreas
transcapillari
transport
tumor
reduc
uptak
drug
approach
sidestep
problem
high
tumor
ifp
improv
treatment
effect
therebi
reduc
incomplet
tumor
respons
rapid
diseas
relaps
develop
drug
resist
due
suboptim
dose
often
seen
use
convent
chemotherapi
use
peptid
target
ligand
offer
sever
advantag
includ
eas
synthesi
structur
simplic
low
cost
low
immunogen
small
size
readi
diffus
simpl
target
formul
assembl
compar
larger
biomolecul
antibodi
previou
studi
show
use
larger
biomolecul
target
ligand
may
increas
clearanc
antibodymodifi
nanoparticl
blood
may
due
nonspecif
bind
uptak
nanoparticl
re
earlier
studi
target
deliveri
system
suggest
target
moieti
increas
drug
accumul
tumor
tissu
howev
target
nanoparticl
alway
caus
signific
increas
overal
tumor
accumul
compar
nontarget
drug
use
macromoleculetarget
ligand
antibodi
transferrin
neglig
impact
tumor
accumul
biodistribut
differenti
effect
nanoparticl
modifi
macromolecul
modifi
small
molecul
may
due
differ
molecular
size
affin
penetr
target
ligand
possibl
target
moieti
high
affin
would
subject
greater
intern
degrad
perivascular
tumor
cell
therebi
limit
penetr
tumor
reduc
tumor
retent
colorect
cancer
one
commonli
diagnos
cancer
lead
caus
cancer
death
worldwid
tradit
chemotherapi
limit
therapeut
efficaci
due
nonspecif
deliveri
tumor
nontumor
cell
develop
drug
resist
cancer
cell
therefor
urgent
need
develop
tumorspecif
target
drug
deliveri
system
accur
effect
deliv
anticanc
chemotherapeut
drug
tumor
site
recent
studi
wu
et
al
use
phage
display
technolog
identifi
three
peptid
could
bind
colorect
cancer
cell
high
specif
bind
affin
author
success
develop
target
drug
conjug
peptid
liposom
novel
target
liposom
drug
combin
specif
deliv
chemotherapeut
tumor
result
much
higher
dose
drug
accumul
tumor
site
significantli
increas
tumor
inhibit
abil
two
type
chemotherapeut
drug
effect
elimin
cancer
without
induc
side
effect
day
trace
recurr
thu
studi
demonstr
drug
accur
deliv
tumor
site
combin
liposom
drug
peptid
gener
use
phage
display
technolog
result
nextgener
target
anticanc
drug
deliveri
system
advanc
nanotechnolog
facilit
multidisciplinari
approach
toward
develop
ideal
smart
nanodrug
deliveri
system
decor
target
ligand
diagnost
imag
use
addit
therapeut
agent
interest
fig
avail
smart
nanodrug
deliveri
system
near
futur
allow
us
detect
diagnos
target
modul
deliveri
track
progress
therapi
remot
noninvas
combinatori
phagedisplay
random
peptid
librari
valuabl
tool
studi
interact
peptid
substanc
materi
past
scientist
focus
identifi
bt
cell
epitop
diseasespecif
antigen
mimic
receptor
agonistsantagonist
enzym
inhibitor
protein
partner
recent
year
increas
number
research
appli
techniqu
new
area
studi
chemistri
materi
scienc
although
phage
display
power
techniqu
still
disadvantag
choos
suitabl
phage
display
librari
e
number
phagedisplay
amino
acid
residu
use
applic
select
condit
ensur
stabil
qualiti
phage
display
librari
follow
appropri
screen
protocol
import
factor
could
impact
qualiti
desir
ligand
peptid
gener
key
paramet
establish
function
target
peptid
like
obtain
furthermor
combin
peptid
inform
phage
display
bioinformat
resourc
may
improv
qualiti
peptid
tian
et
al
sandman
et
al
incorpor
geneticallyencod
nonnatur
amino
acid
phagedisplay
librari
pave
way
wider
chemic
divers
woiwod
et
al
also
combin
new
phagedisplay
hybrid
system
synthet
chemistri
onecompoundoneclon
principl
compound
encod
uniqu
nucleotid
sequenc
insert
noncod
region
phage
genom
new
techniqu
help
advanc
possibl
applic
potenti
phage
display
go
forward
cancer
cell
differ
normal
cell
often
found
overexpress
certain
antigen
molecul
recogn
tumor
antigen
high
specif
suitabl
candid
potenti
agent
guid
cancer
chemotherapi
target
tumor
site
therapeut
monoclon
antibodi
antibodydrug
conjug
adc
peptidedrug
conjug
pdc
peptidemedi
drug
deliveri
system
major
impact
field
cancer
therapi
therapeut
monoclon
antibodi
base
therapi
achiev
remark
clinic
success
becom
one
import
strategi
treat
patient
hematolog
malign
solid
tumor
direct
action
antibodi
receptor
blockad
agonist
activ
may
limit
therapeut
activ
antibodydepend
cellular
cytotox
adcc
complementdepend
cytotox
cdc
demonstr
major
role
antibodi
efficaci
unfortun
antibodi
treatment
patient
malign
tumor
may
achiev
therapeut
effect
due
immun
suppress
immun
escap
complement
inhibit
etc
adc
offer
possibl
overcom
issu
enhanc
cytotox
cancer
cell
therebi
reduc
undesir
side
effect
although
adc
alreadi
approv
anticanc
therapi
remain
sever
limit
type
therapeut
tumor
penetr
high
manufactur
cost
challeng
conjug
chemistri
pdc
similar
promis
adc
differ
pharmacolog
outcom
compar
adc
pdc
addit
advantag
smaller
molecular
mass
higher
tissu
penetr
enhanc
flexibl
welldefin
conjug
chemistri
faster
easier
synthesi
process
prepar
homogen
form
sever
peptid
includ
rgd
motif
peptid
cell
penetr
peptid
tumor
cell
specif
peptid
use
synthes
pdc
cancer
therapi
decad
research
lot
pdc
discov
clinic
evalu
although
none
yet
receiv
regulatori
approv
one
pdc
clinic
evalu
carri
promis
peptidedrug
conjug
coval
link
paclitaxel
proprietari
amino
acid
peptid
ratio
result
phase
trial
show
drug
candid
accept
safeti
profil
current
undergo
phase
ii
trial
demonstr
efficaci
safeti
toler
patient
brain
metastas
nonsmal
cell
lung
cancer
addit
combin
trastuzumab
advanc
phase
ii
studi
therapeut
agent
posit
metastat
breast
cancer
howev
one
major
drawback
pdc
limit
clinic
use
stabil
pdc
highli
proteolyt
unstabl
result
short
halflif
circul
poor
pharmacokinet
addit
rel
small
molecular
weight
pdc
would
rapidli
elimin
renal
excretori
system
neither
adc
pdc
allow
high
drug
payload
conjug
molecul
major
challeng
face
adc
pdc
rel
low
capac
drug
henc
effect
payload
strategi
use
differ
carrier
urgent
need
addit
adc
pdc
nanoparticl
modifi
target
ligand
effect
payload
strategi
nanoparticl
potenti
vehicl
encapsul
chemotherapeut
achiev
higher
drugload
effici
nanoparticl
shown
increas
drugload
capac
approxim
thousandfold
compar
adc
pdc
much
enhanc
drug
load
capac
higher
tumor
cell
specif
render
nanoparticl
potenti
promis
target
drug
result
higher
efficaci
lower
toxic
adc
pdc
peptidemedi
drug
deliveri
system
shown
consider
promis
improv
deliveri
drug
tumor
limit
offtarget
toxic
simultan
target
therapeut
repres
promis
new
frontier
cancer
treatment
despit
advantag
increas
therapeut
efficaci
mani
challeng
still
remain
nanoparticl
includ
potenti
offtarget
effect
ligand
stabil
immun
respons
trigger
drug
deliveri
effici
cytoplasm
target
cell
particular
rapid
clearanc
nanodrug
cell
reticuloendotheli
system
re
mononuclear
phagocyt
system
mp
especi
liver
spleen
lead
increas
toxic
offtarget
organ
reduc
therapeut
efficaci
howev
recent
public
suggest
offtarget
effect
reduc
intralipid
fdaapprov
fat
emuls
use
parenter
nutrit
sourc
could
decreas
toxic
liver
spleen
increas
bioavail
dichloro
platinum
ii
load
hyaluron
acid
polymerco
nanoparticl
dachpthanp
possibl
inhibit
periton
clearanc
impair
phagocyt
activ
kupffer
cell
whether
reduc
target
effect
also
observ
liposom
base
drug
deliveri
system
worthwhil
investig
drug
deliveri
use
antibodi
ligand
bind
specif
receptor
molecul
tumor
target
cell
allow
increas
drug
accumul
target
tumor
site
howev
actual
percentag
drug
accumul
tumor
site
often
percent
total
dose
administ
identif
effect
ligandreceptor
interact
may
help
improv
effect
activ
target
field
target
drug
deliveri
scientist
still
long
way
go
may
chang
within
next
coupl
year
time
number
target
drugdeliveri
nanoparticl
approv
fda
expect
increas
although
cancer
drug
continu
discov
drug
limit
efficaci
cancer
less
ideal
abil
prolong
live
cancer
patient
small
molecul
drug
advantag
higher
tissu
penetr
abil
nonspecif
tumor
rel
short
halflif
protein
drug
highli
tumorspecif
howev
lower
tumor
penetr
abil
due
larger
molecular
size
peptidemedi
drug
deliveri
system
combin
potent
small
molecul
drug
high
specif
peptid
thu
leverag
benefit
two
therapeut
regimen
reduc
disadvantag
ideal
drug
deliveri
system
achiev
high
level
clinic
efficaci
minim
advers
effect
develop
target
liposom
improv
drug
deliveri
target
tissu
reduc
drug
distribut
nontarget
tissu
result
increas
therapeut
activ
minim
side
effect
peptidemedi
liposom
target
tumor
cell
vasculatur
repres
new
gener
chemotherapeut
deliveri
system
offer
superior
pharmacokinet
control
biodistribut
greater
efficaci
enhanc
safeti
profil
simultan
improv
erad
diseas
reduc
common
side
effect
long
soughtaft
goal
develop
chemotherapeut
drug
modular
organ
target
liposom
technolog
make
possibl
combin
peptid
seri
liposom
drug
yield
nextgener
target
agent
peptidemedi
target
liposom
howev
date
peptidedrug
conjug
peptidemodifi
nanoparticl
success
reach
market
howev
certain
hurdl
must
overcom
peptid
wide
use
target
moieti
includ
develop
appropri
ligand
target
receptor
understand
mechan
ligandreceptor
uptak
disposit
traffick
recycl
complianc
chemistri
manufactur
control
cmc
requir
